Drug Profile
Basimglurant - Noema Pharma
Alternative Names: NOE-101; RG-7090; RO-4917523Latest Information Update: 20 Oct 2022
Price :
$50
*
At a glance
- Originator Roche
- Developer Chugai Pharmaceutical; Noema Pharma; Roche
- Class Analgesics; Antidepressants; Antiepileptic drugs; Fluorobenzenes; Halogenated hydrocarbons; Imidazoles; Pyridines; Small molecules
- Mechanism of Action Metabotropic glutamate receptor 5 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Trigeminal neuralgia
- Phase II Tuberous sclerosis
- Discontinued Fragile X syndrome; Major depressive disorder
Most Recent Events
- 18 Oct 2022 Basimglurant - Noema Pharma receives Fast Track designation for Trigeminal neuralgia [PO] in USA
- 28 Feb 2022 Phase-II clinical trials in Tuberous sclerosis (Adjunctive treatment, In children, In adolescents) in USA (Parenteral) (NCT05059327)
- 14 Feb 2022 The US FDA authorises an IND application for a phase IIb clinicial trial of basimglurant in Trigeminal neuralgia